N-809

N/A

Report date: 2025/07/03 16:42:41

Base Information

Drug NameN-809
Drug Alias NameN-809
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsProgrammed death-ligand 1 blockers +[4] 
TargetsProgrammed death-ligand 1Interleukin-15
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunitybio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunitybio Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A